N6F11
Product Specifications
UNSPSC Description
N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+ T cells[1][2][3][4].
Target Antigen
Ferroptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/n6f11.html
Solubility
DMSO : 31.25 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
ClC1=CC=C(C2=CC3=C(C(NC(CCl)=N3)=O)S2)C=C1
Molecular Weight
311.19
References & Citations
[1]Li J, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049.|[2]Liu J, et al. Cell type-specific induction of ferroptosis to boost antitumor immunity. Oncoimmunology. 2023 Nov 20;12(1):2282252. |[3]Shi TM, et al. Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer. J Med Chem. 2024 Feb 22;67(4):2238-2263.|[4]Liu J, et al. Adverse effects of ferroptotic therapy: mechanisms and management. Trends Cancer. 2024 May;10(5):417-429.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-162065/N6F11-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-162065/N6F11-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
851398-76-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
